• Experts optimistic in weight loss drugs as addiction treatment

    Anecdotally, patients on a popular class of weight loss drugs known as glucagon-like peptide receptor agonists are reporting another potential benefit experts are optimistic about: reduced cravings for alcohol. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • Mark Cuban's pharma company to start manufacturing 2 drugs this week

    Mark Cuban Cost Plus Drug Co. plans to begin manufacturing epinephrine and norepinephrine this week at its 22,000-square-foot drug facility in Dallas, Mr. Cuban confirmed to Becker's on March 5. 
  • Drugmakers send CMS counteroffers in fair price negotiations

    Drugmakers that were selected in early February to begin price negotiations for 10 of the most expensive drugs in the U.S. as part of the Biden administration's Inflation Reduction Act have sent the federal government counteroffers, President Joe Biden confirmed in a March 4 update.
  • Post-Change hack, hospital pharmacies ask for paused audits

    As hospital pharmacies try to recover from a nationwide disruption in their claims and e-prescribing technology, the American Society of Health-System Pharmacists is urging HHS to take action. 
  • Ozempic cuts risk of kidney problems in diabetes patients: New data

    Novo Nordisk released results from a clinical trial March 5 that showed Ozempic reduced the risk of kidney disease-related events in patients with Type 2 diabetes. 
  • The efficacy of GLP-1s, compared

    Prescriptions for Ozempic, Wegovy and other glucagon-like peptide-1 receptor agonists are booming among patients seeking to shed pounds. 
  • Where medication abortion is, is not legal

    Fourteen states prohibit medication abortion — a federally approved two-drug regimen that accounts for more than 50% of U.S. abortions — and 15 other states restrict abortion pills, according to NBC News. 
  • Retail pharmacies to begin selling OTC birth control within weeks

    Almost eight months after the FDA approved Opill, the first over-the-counter birth control pill, it will soon be available for purchase without a prescription at pharmacies like CVS and Walgreens in weeks, according to ABC News.
  • CVS, Walgreens to begin selling abortion pills

    A year after the FDA allowed eligible pharmacies a pathway to dispense abortion pill mifepristone, CVS and Walgreens confirmed to Becker's they gained approval and will soon offer the medication. 
  • 8 Ozempic updates

    Health systems are magnifying their weight loss programs as estimates place the global prevalence of obesity at 1 billion adults and children. 
  • RSV shots may be tied to neurological condition

    Fall of 2023 was the first time a vaccine for respiratory syncytial virus became available for those most at risk, but now data shows the shots may have caused a few cases of Guillain-Barré syndrome, The New York Times reported March 1.
  • Health systems double down on weight loss programs

    By 2030, 51% of the world's population, or 4 billion people, are expected to have obesity, according to trends tracked by the World Obesity Federation. 
  • 1 in 3 independent pharmacies to close this year: Survey

    Thirty-two percent of independent pharmacy owners plan to shutter their businesses by the end of 2024, according to a February survey. 
  • Depression, anxiety pill prescriptions rise post-pandemic

    In 2022, overall prescriptions grew 1% from 2019 while mental health-related prescriptions increased 12%, USA Today reported Feb. 29. 
  • 2 in 5 patients prefer to self-medicate

    Almost 40% of patients prefer to self-medicate because doing so has worked for them previously, according to a survey published Feb. 27, led by market research and data analytics firm YouGov.
  • Weight loss drugs wrinkle economies worldwide

    GLP-1s, such as Type 2 diabetes therapies Ozempic and Mounjaro and weight loss drug Wegovy, are expected to bulk up the U.S. economy as more Americans shed pounds. 
  • PBMs not complying with federal probe: FTC

    In June 2022, the Federal Trade Commission launched a probe into the business practices of pharmacy benefit managers and how they affect drug affordability and access. No PBM has fully complied with the probe, FTC Chair Lina Khan said in a recent letter obtained by Axios. 
  • A weight loss drug candidate could rival Ozempic

    Viking Therapeutics reported Feb. 27 strong results from a phase 2 trial of a new drug that could rival other GLP-1 medications like Ozempic, Mounjaro and Wegovy.
  • 2 drugs nearing approval to know: Optum

    UnitedHealth Group's Optum Rx is monitoring two drug candidates that might be approved in the next few months, according to its winter 2024 report. 
  • Mark Cuban's drug company to add another branded med

    Mark Cuban Cost Plus Drug Co. will sell Euthyrox, its 21st brand-name drug, in March. 

Featured Whitepapers

Featured Webinars